Evidence map›Paper›PMID 35416539›Full record

ArticleArchives of osteoporosis2022

Impact of osteoporosis liaison services on the expected lifetime osteoporosis-related medical expenses of patients with fragility fracture in a private hospital in Japan.

Saori Kobayashi, Shinya Tanaka, Yasumasa Yoshino, Hideki Tobita, Kanae Kuwagaki, Rie Fujioka, Hiroaki Totsuka, Yuka Ichiba, Sachiko Ishimine, Kazumi Sakamoto and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of osteoporosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Impact of the guidance on fracture Liaison Services and the introduction of a new fee for secondary fracture prevention in Japan: Implementation of secondary fracture prevention during hospitalization for fragility fractures.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Saori KobayashiOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Shinya TanakaOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan. uf8s-tnk@asahi-net.or.jp.
Yasumasa YoshinoOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Hideki TobitaOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Kanae KuwagakiOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Rie FujiokaOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Hiroaki TotsukaOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Yuka IchibaOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Sachiko IshimineOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Kazumi SakamotoOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Hikaru OhamaOsteoporosis Liaison Service, Saitama Jikei Hospital, Saitama, Japan.
Toshiro KuboSaitama Jikei Hospital, Saitama, Japan.
Social Insurance Saitama Chuo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the efficacy of a Japanese fracture liaison service (FLS), the osteoporosis liaison service (OLS), in suppressing osteoporosis-related expenses from the public insurance by preventing secondary fracture in spite of higher medication costs during expected life spans. OLS could reduce medical expenses for osteoporosis in all age groups. PURPOSE: Osteoporosis liaison services (OLS), which are based on fracture liaison services (FLS), are used in Japan to prevent both primary and secondary fractures in older people. We aimed to clarify the effects of OLS on the medical expenses. PATIENTS AND

methodsWe compared patients with fragile fractures hospitalized to Saitama Jikei Hospital before and after implementing OLS. These were labeled a non-OLS group and an OLS group, and they were further organized by age (< 75, 75-84, and ≥ 85 years). The expected osteoporosis-related medical expenses during life were calculated by the occurrence, fracture site, medication, and life expectancy and compared between the non-OLS and OLS groups by the age group.

resultsThe non-OLS group included 400 people (100 males and 300 females, mean age 81.7 ± 9.7 years), comprising 154 with vertebral fractures and 246 with hip fractures. The OLS group included 406 patients (101 males and 305 females, mean age 82.4 ± 9.3 years), of whom 161 had vertebral fractures and 245 had hip fractures. The suppressive secondary fracture effects of OLS were previously reported. The expected expense of osteoporosis treatment in the OLS group was found to be greater than that in the non-OLS group for all age groups. In contrast, expected expenses for treating secondary fractures were shown to increase more in the non-OLS group. However, total expenses were lower in the OLS group across all age groups.

conclusionThe implementation of OLS can reduce overall healthcare costs despite the increased expenses required to provide medical therapy and periodic examinations.

Indexed as

Bone Density Conservation AgentsHip FracturesOsteoporosisOsteoporotic FracturesSpinal FracturesAgedAged, 80 and overFemaleHospitals, PrivateHumansJapanMaleSecondary PreventionBone Density Conservation AgentsFragile fractureHip fractureOsteoporosis liaison service/fracture liaison serviceSecondary fractureSuper-aging societyVertebral fracture

Identifiers

PMID35416539
OpenAlexW4223445924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.